PAK kinase inhibition has therapeutic activity in novel preclinical models of Adult T-cell Leukemia/Lymphoma.

CONCLUSIONS: PAK2, a gene frequently amplified in ATLL, facilitates CADM1-mediated stromal interaction and promotes survival of ATLL cells. Taken together, PAK inhibition may hold significant promise as a targeted therapy for aggressive ATLLs.
PMID: 30862694 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 11, 2019 Category: Cancer & Oncology Authors: Chung EYL, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, Ren X, Pradhan K, Bartholdy B, Wei X, Zou Y, Zhang J, Ogawa S, Steidl U, Zang X, Verma A, Janakiram M, Ye BH Tags: Clin Cancer Res Source Type: research